Thierry Andre Roumeguere

Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis.

Silke Gillessen, Ananya Choudhury, Alejo Rodríguez‐Vida et al. · Journal of Clinical Oncology · 2021 · 36 citations

Medicine, Oncology, Pharmacotherapy +17

Avelumab as the basis of neoadjuvant regimen in platinum-eligible and -ineligible patients with nonmetastatic muscle-invasive bladder cancer: AURA (Oncodistinct-004) trial.

Nieves Martínez Chanzá, Aurélien Carnot, Philippe Barthélémy et al. · Journal of Clinical Oncology · 2022 · 19 citations

Medicine, Oncology, Urology +14

A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532)

Bertrand Tombal, F. Gómez-Veiga, Á. Gómez-Ferrer et al. · European Urology Oncology · 2024 · 15 citations · Full text

Medicine, Oncology, Urology +17